Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Erik S.G. Stroes; David Colquhoun; David Sullivan; Fernando Civeira; Robert S. Rosenson; Gerald F. Watts; Éric Bruckert; Leslie Cho; Ricardo Dent; Beat Knüsel; Allen Xue; Robert C. Scott; Scott M. Wasserman; Michael Rocco

doi:10.1016/j.jacc.2014.03.019

Keywords

MedicinePCSK9StatinCholesterolAntibodyLdl cholesterolInternal medicineImmunologyLDL receptorLipoprotein

Affiliated Institutions

Related Publications

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

Paul M. Ridker

Twenty-two years ago, the landmark 4S trial demonstrated that statin therapy could reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among second...

2016 European Heart Journal 255 citations

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Scott M. Grundy , James I. Cleeman , C. Noel Bairey Merz +6 more

The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the pub...

2004 Circulation 6899 citations

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT

Erin A. Bohula , Robert P. Giugliano , Christopher P. Cannon +6 more

Background— Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C an...

2015 Circulation 327 citations

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

Peter H. Jones , Michael H. Davidson , Evan A. Stein +5 more

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin acros...

2003 The American Journal of Cardiology 1382 citations

Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])

Harold Bays , Carlos A. Dujovne , Mark E. McGovern +4 more

This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...

2003 The American Journal of Cardiology 153 citations

Publication Info

Year: 2014
Type: article
Volume: 63
Issue: 23
Pages: 2541-2548
Citations: 523
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

523

OpenAlex

Cite This

APA Style

                            
                                
                                    Erik S.G. Stroes, 
                                
                                    David Colquhoun, 
                                
                                    David Sullivan
                                
                                et al.
                            
                            (2014). 
                            Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. 
                            Journal of the American College of Cardiology
                            , 63
                            (23)
                            , 2541-2548.
                            https://doi.org/10.1016/j.jacc.2014.03.019
                        

Identifiers

DOI: 10.1016/j.jacc.2014.03.019